Global Cardio Care Centers is the world’s first and largest outpatient EECP center with a multi-specialty physician group practice dedicated to using EECP as a primary treatment for cardiovascular diseases. Global Cardio Care Centers’ medical staff delivers upwards of 30,000 hours of EECP annually.
Patients who visit Global Cardio Care Centers are seen by physicians who are less concerned with billing, scheduling, marketing or insurance due to the expertise provided by Global Cardio Care, Inc. Physicians who join Global Cardio Care Centers are invited to integrate exercise, nutrition and education into overall cardiovascular treatment with EECP at its core with a goal to promote and empower people to live a healthier, longer life. Sara Soulati and her executive team manage Global Cardio Care Centers, a physician practice since 2002.
Ronald Seymour Weaver was born in New York City in 1949. His interest in medicine started at an early age due to major influences from his father, also a physician, who dedicated his life’s work to caring for many unfortunate people in the South Bronx.
Dr. Weaver lived in a neighborhood where public schools could not provide the education his parents felt he should have, so in the 4th grade, he attended the United Nations International School in Manhattan. While there, he studied Latin and other courses in preparation for medical school.
Dr. Weaver graduated from Hobart College in 1970 and Cornell University Medical College in 1974; completed a medical internship in 1975 at Harlem Hospital, a Columbia University Teaching Hospital; and, became fully licensed to practice medicine in the summer of 1975.
To complete his Internal Medicine training, he transferred to the University of California, Los Angeles, UCLA. During his second year at UCLA, Dr. Weaver was accepted into the UCLA specialty program for pulmonology, lung diseases, which was to begin one year after finishing his Internal Medicine program in 1978. He had taken and passed the specialty boards to became board certified in Internal Medicine in 1977.
After his training, in internal medicine, Dr. Weaver began practice in the South Central Los Angeles and Inglewood communities of Southern California. He became attached to the community and his patients and elected to forgo his ambition as a lung specialist and remained in the community. His clinic in Inglewood’s African-American community has included hundreds of hours of free medical care to people who could not afford the treatments on their own.
Throughout his career, Dr. Weaver has been a community leader under many different hats. He was on the medical staff board of Daniel Freeman Hospital in Inglewood and was managing partner of a seven-physician medical group that included a medical laboratory and a diagnostic testing company. He served as chief financial officer for an independent physician association as well as other non-medical organizations.
Dr. Weaver has always studied and sometimes incorporated cutting edge treatments into his practice. In 2002,he personally discovered the benefits of a new primarily cardiovascular treatment that had become FDA approved in the late 1990's know as Enhanced External Counter pulsation, EECP.
Together with Sara Soulati, one of the world’s foremost authority on EECP treatment, Dr. Weaver launched Global Cardio Care Centers, the world’s largest primary EECP practice. The practice specializes in non invasive cardiovascular disease treatments and provides EECP therapy to people affected by many other diseases and illnesses.
Dr. Weaver is currently vice chairman of the National Medical Association's judicial council, the largest African American physician association in America.
Over 35 days (and longer), for one hour daily you receive EECP treatment, the core of the Global Cardio Care Centers program. Those who complete an entire course of treatment receive more benefit long term.
If an artery becomes clogged, our body’s natural defense is to develop new arteries, called collaterals. EECP helps your body grow collaterals and naturally bypass the blockage. It is all about circulation and how well oxygenated blood flows through the body. EECP stimulates production of a hormone called vascular endothelial growth factor (VEGF). EECP also enhances secretion of a vasodilator called nitrous oxide. Because of the increased levels of VEGF and nitrous oxide, these collaterals become larger and wider. With the increased flow of oxygen-rich blood throughout the body, the heart and all other organs functionally improve.
There are more than 900 academic institutions and independent physician practices throughout the U.S and the world that use EECP therapy for cardiovascular disease. They include:
The device used for EECP was invented in the late 1950s at Harvard University.
The U.S. Food and Drug Administration cleared EECP in:
Early counterpulsation therapy was done with hydraulics at Harvard University.
EECP works by pumping blood from the legs upward to the heart while the heart is at rest. This mechanism improves circulation throughout the body, promotes angiogenesis, and has long-term, positive effects.
(1) You lie on a comfortable EECP bed. Three large blood-pressure-like cuffs wrap around the (2) calves, (3) thighs, and (4) buttocks. (5) You are hooked to a heart monitor.
To optimize therapeutic benefit, the cuffs are timed to a patient’s ECG squeezing calves, thighs and buttocks in rapid sequence. When the heart is at rest, in early diastole the cuffs inflate sequentially from distal to proximal, and then deflate in late diastole prior to onset of systole.
Sequential cuff inflation creates a retrograde pressure wave that augments diastolic pressure, increasing pressure of coronary perfusion and venous return to the right side of the heart. This increases preload and cardiac output.
Rapid, simultaneous cuff deflation decreases systemic vascular resistance, after load, and cardiac workload.
The squeezing mechanism of EECP improves the hemodynamics of blood flow and shear stress to help generate progenitor and hematopoietic stem cells in the bone marrow improving endothelial function and reprofusing organ tissue.
In addition, elevated levels of nitric oxide and vascular endothelial growth factor are evident during EECP that helps improve circulation as well as stimulates angiogenesis, resulting in improved endothelial function and a reduction of both circulating inflammatory markers and arterial stiffness.
The Centers for Medicare and Medicaid Services (CMS) and other third-party insurance payers have been providing reimbursement for the treatment of angina symptoms since 1999.
EECP promotes angiogenesis to help grow new collaterals for blood to flow, like a NaturalBypass® around blocked arteries.
Post-Invasive Patients. These are patients who have had Bypass Surgery (CABG) or Percutaneous Coronary Intervention (PCI) within the last five years or more. Statistics show that these patients will be symptomatic as early as one year post procedure. EECP is a safe, non-invasive treatment option.
Diabetic patients with underlying ischemic heart disease. These are patients who suffer from neuropathy and often have symptoms of shortness of breath on physical exertion. Many of these patients are NOT good candidates for surgery as many have excessive risk factors and post-operative complications.
Inactive or Sedentary Lifestyle. These patients avoid any activity that brings them discomfort. Many experts say that EECP therapy provides as much as six times the amount of exercise benefit per hour of treatment than any other form of tolerated physical exercise. Many of these patients are obese or elderly with many health complications that pose significant risk factors for other traditional invasive procedures.
Post PCI and EECP. Clinical studies have shown that there is a definite trend demonstrating EECP therapy, when done post PCI, may reduce restenosis rates.
“PCI and CABG target the lesion. EECP with its mechanisms of action targets the disease.”
– Ozlem Soran, MD, MPH, FACC, FESC. Director of EECP Research Lab, Associate Professor of Medicine, Epidemiology and Research, University of Pittsburgh, Heart and Vascular Institute
A course of EECP therapy is 35 hours and more.
Although the patient benefits of EECP therapy have been proven to last for more than 5 years, it is not uncommon for Medicare or other third-party payers to reimburse for repeat treatment session (35 days) twice each year.
Throughout the years, randomized, controlled clinical trials have been conducted to prove the efficacy of EECP for angina pectoris. There have been more than 200 published papers in peer-reviewed medical journals demonstrating safety and efficacy of EECP in the treatment of angina pectoris and chronic heart failure.
“The long-term care of patients with chronic coronary artery disease requires the cardiologist to use aggressive preventive methods and more cost-effective treatment to improve clinical and financial outcomes. EECP treatment is a safe, cost-effective, non-invasive method of restoring myocardial perfusion and reducing symptoms of angina. EECP treatment is the perfect disease management tool for chronic coronary artery disease.”
– John E. Strobeck, MD, PhD, Interventional Cardiologist, Co-founder of the Heart Failure Society of America, Medical Director, The Heart & Lung Center, Hawthorne, NJ
Enhanced External Counterpulsation Treatment Improves Arterial Wall Properties and Wave Reflection Characteristics in Patients With Refractory Angina
Nichols WW, Estrada JC, Braith RW, Owens K, Conti CR.
Journal of the American College of Cardiology. 2006 Sep 19;48(6):1209-1215. Epub 2006 Aug 25.
Summary: 34, 1-hour EECP treatments in 20 stable angina patients caused a significant decline in the augmentation index and an increase in reflected wave travel time, demonstrating improvement in endothelial function.
The Effect of External Counterpulsation Therapy on Circulating Endothelial Progenitor Cells in Patients with Angina Pectoris
Yosef O, Rosenthal E, Barbash IM, Matetzky S, Tal R, Bentancur AG, Sela BA, Nagler A, Leor J.
Cardiology. 2008;110(3):160-6. Epub 2007 Dec 4.
Summary: Circulating endothelial progenitor cells (EPCs) positive for CD34 measured by flow cytometry and kinase insert domain receptor (KDR) measured by the number of colony-forming units in 25 patients with angina pectoris randomized to 35 daily 1-hour EECP treatment sessions (n=15) and control (n=10) were significantly increased in the EECP-treated group and not in the control group. Patients in the EECP-therapy group also improved their anginal score from 3.0 pre-EECP therapy to 2.0 post EECP therapy (p<0.001). The improvement of angina post EECP treatment is associated with an increased number of colony-forming capacities of circulating EPCs.
At Vasomedical, there is a bibliography of clinical research and evidence-based documentation proving benefit of EECP treatment.
Studies are available on many of the following:
Call today to schedule a Free EECP session and to enroll them for a course of 35 EECP treatments and more.
Global Cardio Care – West Los Angeles
11860 Wilshire Blvd.
Los Angeles, CA 90025
Global Cardio Care – Inglewood
633 Aerick Street
Inglewood, CA 90301